August 17th, 2021 – Medicinal Genomics Assay Receives AOAC’s First Certification for Cannabis Flower and Infused Edibles – MGC is the first manufacturer to receive certification for cannabis-infused edibles and is also the first to offer AOAC-approved cannabis assays for two different qPCR machines: Agilent AriaMX and BioRad CFX96.
August 17th, 2021 – AOAC Approves Two New Microbiological Assays – The Medicinal Genomics platform can detect four species, including A. flavus, A. fumigatus, A. niger, and A. terreus in both flower and infused edibles. The PathoSEEK microbial testing platform uses a PCR-based assay and provides an internal plant DNA control for every reaction.
July 1, 2021 – Growth Media Used in Total Yeast and Mold Testing Can Significantly Affect Microbial Diversity, Study Finds – The growth media used in plating-based total yeast and mold count (TYMC) tests can dramatically impact the diversity of microbes that grow, according to a new investigation from scientists at Medicinal Genomics, a specialist cannabis testing and genetics screening firm.
May 18th, 2021 – Medicinal Genomics Hires Sherman Hom as New Director of Regulatory Affairs Medicinal Genomics has hired Sherman Hom, Ph.D. to be their first director of regulatory affairs. Dr. Hom is coming from a position at New Jersey’s Division of Public Health and Environmental Laboratories (PHEL) where he was the leading research scientist for the state’s cannabis testing lab as well as coordinating their pre-analytical activities for SARS-CoV-2 testing.
March 16th, 2021 – Medicinal Genomics Selects Soquimica as its Distribution Partner in Portugal Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced an agreement with Soquimica to be its distribution partner in Portugal.
August 20th, 2020 – Rose City Labs Adopts Medicinal Genomics’ qPCR Technology for Cannabis Testing Rose City Labs, a multistate state operating organization, has selected Medicinal Genomics’ PathoSEEK® qPCR platform for microbial testing in its Portland, OR, facility, the first in that state.
July 30, 2020 – PharmLabs, First Hemp Lab in Texas, Selects Medicinal Genomics for Microbial Testing Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety and transparency of cannabis, today announced that PharmLabs, a multistate testing lab organization, has selected Medicinal Genomics’ PathoSEEK® qPCR platform for microbial testing in its Texas hemp lab, the first in that state.
May 05, 2020 – Medicinal Genomics to Launch Medical Practicum at CannMed 2020 The biggest barrier to using medicinal cannabis is that the endocannabinoid system and its related pathologies are not taught in medical school, and as a result, physicians cannot help their patients use cannabis as an effective and safe medication
April 2, 2020 – Medicinal Genomics to Donate a Portion of CannMed Tickets Sales to COVID-19 Response Premier medical & scientific cannabis conference to contribute 10% of ticket sales to support CDC Emergency Response Fund to help mitigate the public health threat
March 10, 2020 – Medicinal Genomics Signs on as Agilent US Value Added Reseller MGC will sell Agilent’s Aria qPCR instruments and Bravo, Agilent’s liquid handling DNA purification and lab automation platform in the U.S